Stockscreener 앱 받기
0.1904
2.91%
-0.0057
시간 외 거래:
.19
-0.0004
-0.21%
전일 마감가:
$0.1961
열려 있는:
$0.2099
하루 거래량:
1.42M
Relative Volume:
0.67
시가총액:
$25.81M
수익:
$1.47M
순이익/손실:
$-23.06M
주가수익비율:
-0.8373
EPS:
-0.2274
순현금흐름:
$-19.64M
1주 성능:
-3.89%
1개월 성능:
-16.01%
6개월 성능:
-70.98%
1년 성능:
-67.29%
1일 변동 폭
$0.1818
$0.2099
1주일 범위
$0.1818
$0.214
52주 변동 폭
$0.17
$0.94
VolitionRX Ltd Stock (VNRX) Company Profile
명칭
VolitionRX Ltd
전화
646 650 1351
주소
No. 24-05 Shaw Centre, 1 Scotts Road, Singapore, TX
Compare VNRX vs TMO, DHR, IDXX, A, WAT
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VNRX
VolitionRX Ltd
|
0.1904 | 25.81M | 1.47M | -23.06M | -19.64M | -0.2274 |
|
TMO
Thermo Fisher Scientific Inc
|
464.37 | 172.51B | 44.56B | 6.72B | 6.29B | 17.74 |
|
DHR
Danaher Corp
|
187.32 | 132.46B | 24.57B | 3.60B | 5.26B | 5.051 |
|
IDXX
Idexx Laboratories Inc
|
573.82 | 45.69B | 4.30B | 1.06B | 1.04B | 13.08 |
|
A
Agilent Technologies Inc
|
111.51 | 31.51B | 7.07B | 1.29B | 993.00M | 4.5355 |
|
WAT
Waters Corp
|
286.57 | 28.11B | 3.17B | 642.63M | 516.49M | 10.77 |
VolitionRX Ltd Stock (VNRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-08 | 개시 | H.C. Wainwright | Buy |
| 2023-02-01 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2022-02-17 | 재개 | Cantor Fitzgerald | Overweight |
| 2021-03-10 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-05-16 | 개시 | Maxim Group | Buy |
| 2018-05-14 | 재확인 | The Benchmark Company | Buy |
| 2016-09-07 | 재확인 | Rodman & Renshaw | Buy |
| 2016-02-01 | 개시 | Rodman & Renshaw | Buy |
모두보기
VolitionRX Ltd 주식(VNRX)의 최신 뉴스
VolitionRx announces automated Nu.Q Vet Cancer Test with Fujifilm Vet Systems - Yahoo Finance
VolitionRx shares jump as feline cancer blood test delivers strong accuracy results - MSN
VolitionRx (VNRX) Completes Key Phase for Nu.Q Vet Cancer Test i - GuruFocus
Volition announces first ever automated Nu.Q® Vet cancer test with Fujifilm Vet Systems - marketscreener.com
Automated cancer screening test set for Japan’s 7M pet dogs - Stock Titan
Tax withholding on VolitionRx (VNRX) shares for officer via RSU settlement - Stock Titan
VolitionRx (VNRX) CCO covers tax bill via 2,283-share cancellation - Stock Titan
Tax withholding trims VolitionRx (VNRX) GC Nicholas Plummer’s shares - Stock Titan
VNRX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
VolitionRx issues shares to satisfy debt obligations and completes private placement - Investing.com
VNRX SEC FilingsVolitionrx 10-K, 10-Q, 8-K Forms - Stock Titan
VolitionRx (VNRX) grants CCO 149,000 RSUs in lieu of cash pay - Stock Titan
Ethel Rubin receives 178,000 RSU award at VolitionRx Ltd (VNRX) - Stock Titan
Executive at VolitionRx (VNRX) awarded 142,000 RSUs in lieu of cash pay - Stock Titan
VOLITIONRX (VNRX) CFO awarded 202,000 RSUs in lieu of cash pay - Stock Titan
119,000 RSUs granted to VolitionRx (VNRX) secretary in lieu of cash pay - Stock Titan
VolitionRx (VNRX) grants 187,000 RSUs to General Counsel Plummer - Stock Titan
[Form 4] VOLITIONRX LTD Insider Trading Activity - Stock Titan
VolitionRx (VNRX) executive receives 173,000 RSUs instead of cash pay - Stock Titan
VolitionRx (VNRX) grants CSO 149,000 RSUs instead of cash - Stock Titan
Director at VolitionRx (VNRX) granted 178,000 RSUs in lieu of cash - Stock Titan
VolitionRx advances cancer tests, expects French reimbursement By Investing.com - Investing.com Australia
VolitionRx Reports Clinical and Commercial Progress Across Cancer Detection and Sepsis Monitoring Platforms - citybuzz -
VolitionRx advances cancer tests, expects French reimbursement - Investing.com
VolitionRx Highlights Commercial Momentum and Multi-Pillar Execution - Yahoo Finance
Simple blood test finds most cat lymphomas, unlocks $5M for VolitionRx - Stock Titan
VolitionRx issues shares to satisfy debt and completes private placement - Investing.com South Africa
VolitionRx (NYSE: VNRX) issues shares to repay Lind note - Stock Titan
Q3 2025 VolitionRX Ltd Earnings Call Transcript - GuruFocus
Should You Buy VolitionRX Ltd (VNRX) Today? Analysis, Price Targets, and 2026 Outlook. - Intellectia AI
Armistice Capital reports 4.99% stake in VolitionRx (VNRX) — 6.45M shares - Stock Titan
Guidance Update: Is VolitionRx Limited gaining market share2025 Trading Volume Trends & Weekly Watchlist of Top Performers - baoquankhu1.vn
Volume Summary: Is now the right time to enter VolitionRx LimitedJuly 2025 Retail & Step-by-Step Trade Execution Guides - mfd.ru
VolitionRx nears 100 Nu.Q Discover clients, extends reach to Japan - Stock Titan
VolitionRx receives NYSE American non-compliance notice By Investing.com - Investing.com Australia
VolitionRx (VNRX) Plans to Offer Nearly 18 Million Shares - GuruFocus
VolitionRx (VNRX) Faces NYSE American Compliance Challenge - GuruFocus
VolitionRx Gets NYSE American Non-Compliance Notice for Failing Equity Requirements - marketscreener.com
VolitionRx Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
VolitionRx stock gets 'below compliance' tag after NYSE warning - Stock Titan
Volume Report: Is VolitionRx Limited affected by consumer sentimentJuly 2025 Earnings & Intraday High Probability Setup Alerts - baoquankhu1.vn
VolitionRx Prepares French Reimbursement Submission for Nu.Q Cancer Blood Tests - MEXC
VolitionRx (VNRX) Moves Forward with French Reimbursement Submis - GuruFocus
VolitionRx Limited Announces the Preparation of Reimbursement Submission for its Nu.Q® Cancer Assays - Yahoo Finance
What is the cash position of VolitionRx LimitedWeekly Market Report & High Conviction Investment Ideas - mfd.ru
Aug Wrap: Is VolitionRx Limited benefiting from innovation trendsMarket Activity Report & Growth Focused Stock Pick Reports - baoquankhu1.vn
VNRX: D. Boral Capital Maintains Buy Rating and $3 Price Target - GuruFocus
VolitionRx (VNRX) Expands Nu.Q Vet Cancer Test Reach in U.S. and Asia - GuruFocus
Dog cancer blood test expands to all 50 states and parts of Asia - Stock Titan
VolitionRX (VNRX) Receives Buy Rating, Price Target Maintained a - GuruFocus
Why VolitionRx Limited stock is popular among millennialsEarnings Growth Report & Expert Curated Trade Setups - Улправда
VolitionRX Ltd (VNRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.34%
0.59%
자본화:
|
볼륨(24시간):